CYP2C19基因多态性对伏立康唑不良反应发生率的影响

Abstract
Figure/Table
References (22)
Related Citation (15)

Download: PDF (613 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the correlation between CYP2C19 gene polymorphism associated with Voriconazole metabolism and the incidence of adverse reactions, so as to provide reference for clinical individualized administration. Methods A total of 1935 patients with CYP2C19 gene test in Anhui Provincial Hospital from January 2017 to March 2018 were selected, and the proportion of genotypes was analyzed; whether or not Voriconazole was used and whether there were adverse reactions were judged by medical record inquiry, and the incidence of adverse reactions after using Voriconazole in patients with different genotypes was analyzed. Results The incidence of CYP2C19 fast (*1/*1), medium (*1/*2, *1/*3) and slow metabolism (*2/*2, *2/*3 and *3/*3) in 1935 patients were 46.05%, 41.34% and 12.61%, respectively. Voriconazole was used in only 16 of 1935 patients. The rates of adverse reactions in fast (*1/*1), moderate (*1/*2, *1/*3), slow(*2/*2, *2/*3) metabolic patients were 20% and 45% respectively. Conclusion CYP2C19 gene polymorphism is correlated with the incidence of adverse drug reactions of Voriconazole, which has important guiding significance for individualized drug use in patients.

Key words： CYP2C19 Voriconazole Gene polymorphisms Adverse reactions

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Yi1 ZHANG Lei2 FENG Xiaojun2 WANG Ya′nan1 SHEN Aizong2 LIU Sheng1
	2

Cite this article:

LI Yi1 ZHANG Lei2 FENG Xiaojun2 WANG Ya′nan1 SHEN Aizong2 LIU Sheng1,2. Effect of CYP2C19 gene polymorphism on incidence of adverse drug reactions in Voriconazole[J]. 中国医药导报, 2019, 16(6): 8-11.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I6/8

[1] 张淑娟，蔡然，赖斌，等.伏立康唑肝毒性风险因素研究[J].河北医药，2016，38（4）：617-620.
[2] 蔡然，戴富林，张杰根，等.伏立康唑肝毒性研究进展[J].中国医药，2013，8（11）：1679-1680.
[3] 王晶晶，何瑾，王露婕，等.61例伏立康唑血药浓度结果分析[J].中国医院药学杂志，2016，36（9）：770－773.
[4] 梁峰华，孟冬梅，谢慧，等.CYP2C19基因多态性对侵袭性真菌感染重症患者伏立康唑血药浓度的影响[J].中国医院药学杂志，2015，35（16）：1456-1461.
[5] Zhu L，Brüggemann RJ，Uy J，et al. CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects [J]. J Clin Pharmacol，2017，57（2）：235-246.
[6] 邵贝贝，赵宁民，段虹飞，等.基于基因多态性的伏立康唑药代动力学研究状况[J].中国临床药理学杂志，2016， 32（7）：663-666.
[7] Li ZW，Peng FH，Yan M，et al. Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients [J]. Ther Drug Monit，2017，39（4）：422-428.
[8] Crews KR，Gaedigk A，Dunnenberger HM，et al. Clinical Pharmacogenetics Implementation Consortium （CPIC） Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 （CYP2D6） Genotype[J]. Clin Pharmacol Ther，2012，91（2）:321-326.
[9] 邵贝贝.基于CYP2C19、CYP2C9、CYP3A4、ABCB1基因多态性的伏立康唑个体化用药研究[D].郑州：郑州大学，2017.
[10] Amsden JR，Gubbins PO. Pharmacogenomics of triazole antifungal agents：implications for safety，tolerability and efficacy [J]. Expert Opin Drug Metab Toxicol，2017，13（11）：1135-1146.
[11] Mahmoudi M，Brenner T，Hatiboglu G，et al. Substantial Impairment of Voriconazole Clearance by High-Dose Mero-penem in a Patient With Renal Failure [J]. Clin Infect Dis，2017，65（6）：1033-1036.
[12] Sienkiewicz B，Urbaniak-Kujda D，Dybko J，et al. Influence of CYP2C19 Genotypes on the Occurrence of Adverse Drug Reactions of Voriconazole among Hematological Patients after Allo-HSCT [J]. Pathol Oncol Res，2018， 24（3）：541-545.
[13] 杨中卫，唐友勇，石明，等.伏立康唑治疗COPD合并肺真菌感染的不良反应分析[J].湖北医药学院学报，2017， 36（2）：146-150.
[14] Cojutti P，Candoni A，Forghieri F，et al. Variability of Voriconazole Trough Levels in Haematological Patients： Influence of Comedications with cytochrome P450（CYP） Inhibitors and/or with CYP Inhibitors plus CYP Inducers [J]. Basic Clin Pharmacol Toxicol，2016，118（6）：474-479.
[15] 李国栋，刘震，冯端浩.伏立康唑致CYP2C19慢代谢型患者肝损害1例[J].药物流行病学杂志，2012，21（9）：463-464.
[16] Hamadeh IS，Klinker KP，Borgert SJ，et al. Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections [J]. Pharmacogenet Genomics，2017，27（5）：190-196.
[17] Chuwongwattana S，Jantararoungtong T，Chitasombat MN，et al. A prospective observational study of CYP2C19 polymorphisms and voriconazole plasma level in adult Thai patients with invasive aspergillosis [J]. Drug Metab Pharmacokinet，2016，31（2）：117-122.
[18] 裴媛，周贺伟.CYP2C19基因多态性检测指导经皮冠状动脉介入术后患者氯吡格雷个体化用药[J].中国医院用药评价与分析，2017，17（5）：667-669.
[19] 徐晓晨，刘跃辉，塔娜，等.CYP2C19基因多态性及与其代谢相关药物的研究[J].中国现代医生，2018，56（1）：165-168.
[20] 王晋星一，刘倩，严进红，等.CYP2C19基因多态性对氯吡格雷低反应影响的系统评价[J].中国医院用药评价与分析，2017，17（6）：806-809，813.
[21] 陈建秋，章颖，胡彬彬，等.CYP2C19基因多态性对氯吡格雷治疗急性脑梗死的疗效影响[J].中国现代医生，2017， 55（23）：6-9.
[22] Ebrahimpour S，Namazi S，Mohammadi M，et al. Impact of Polymorphisms on Serum Concentration of Voriconazole in Iranian Hematological Patients [J]. J Res Pharm Pract，2017，6（3）：151-157.